Report Summary
Eternity Insights can provide a deep dive research report highlighting the market and competitive in-telligence across the key segments of the market. The report also considers the impact of COVID-19 on the global Cancer Drugs market. The report considers 2018-2020 historic period, 2021 as base year, and 2022-2028 as forecast period. The report includes quantitative analysis of the market supported by the mar-ket drivers, challenges, and trends to accurately map the market scenario and competition.
Cancer Drugs market report is based on robust research methodology designed using blend of research ap-proaches developed using secondary/desk research and validated through the primary research and expert insights. Eternity Insights also uses paid data bases such as FACIVA, Hoovers, and other bench-marking and forecasting tools to provide accurate statistical analysis of supply and demand trends.
To learn more about this report
Key Research Highlights: Market Drivers
The Cancer Drugs market is estimated to expand at a considerable growth rate during the forecast period ow-ing to increasing prevalence of venous diseases and increasing new product approvals to cater this demand. Rise in the awareness about the diseases, increasing importance of early diagnosis, and growing spending on chronic diseases are poised to boost the market growth. Moreover, the key players in the market are investing in research and development of technologically advanced products leading to increased utilization of the Cancer Drugs products across developed and developing countries of the world.
Key Research Highlights: Market Restrains
Limited awareness about the diseases, high cost of products, low economical condition, and lack of favorable insurance systems restricts the adoption of Cancer Drugs products across developing regions of the globe. However, launch of new products with low cost and increasing efforts for market penetration in these regions can offer lucrative growth opportunities for the players in the Cancer Drugs market.
To learn more about this report
Key Research Highlights: Trends
Increasing research and development spending on Cancer Drugs development has been the leading industry trend of Cancer Drugs market
The leading players in the market are focused on developing products which are cost effective and high quality to tap the huge unaddressed opportunities in the developing regions. This can be wit-nessed from the increasing spending on research and development and growing number of new product approvals.
Global Cancer Drugs Market Size, 2018-2028 (USD MILLION)
To learn more about this report
Market Segmentation
| Report Attributes |
Details |
| The market size value in 2021 |
USD XX.XX Million |
| CAGR (2021 - 2028) |
XX.XX % |
| The Revenue forecast in 2028 |
USD XX.XX Million |
| Base year for estimation |
2021 |
| Historical data |
2018-2019 |
| Forecast period |
2022-2028 |
| Quantitative units |
- Revenue in USD Million
- CAGR from 2021 to 2028
|
| Report coverage |
Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
| Segments covered |
By Type Outlook, Application Outlook, Regional Outlook |
| By Type Outlook |
Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy (Biologic Therapy), Others |
| By Application Outlook |
Blood Cancer, Breast Cancer, Gastrointestinal Cancer, Prostate Cancer, Respiratory/Lung Cancer, Other Cancers |
| Regional scope |
North America, Europe, Asia Pacific, Latin America, Middle East & Africa |
| Country scope |
U.S., Canada, U.K., Germany, France, BENELUX, China, India, Japan, South Korea, Brazil, Saudi Arabia, UAE, Turkey |
| Key companies profiled |
Roche, Novartis, Celgene, Bristol-Myers Squibb, Amgen, Johnson & Johnson, Pfizer, Takeda, Eli Lilly, AstraZeneca, Astellas, Merck & Co., Sanofi, Bayer, Biogen Idec, Eisai, Teva, Otsuka, Merck KGaA, Ipsen, AbbVie, Gilead Sciences |
| Customization Available |
Yes, the report can be tailored to meet your specific requirements. |
Key Market Players
- Roche
- Novartis
- Celgene
- Bristol-Myers Squibb
- Amgen
- Johnson & Johnson
- Pfizer
- Takeda
- Eli Lilly
- AstraZeneca
- Astellas
- Merck & Co.
- Sanofi
- Bayer
- Biogen Idec
- Eisai
- Teva
- Otsuka
- Merck KGaA
- Ipsen
- AbbVie
- Gilead Sciences
Cancer Drugs Market, By Type
- Chemotherapy
- Targeted Therapy
- Immunotherapy
- Hormonal Therapy (Biologic Therapy)
- Others
Cancer Drugs Market, By Application
- Blood Cancer
- Breast Cancer
- Gastrointestinal Cancer
- Prostate Cancer
- Respiratory/Lung Cancer
- Other Cancers
Key Benefits To The Stake Holders
- Qualitative and quantitative analysis of the market based on segmentation involving both economic as well as non-economic factors
- Provision of market value (USD Billion) and volume (Tons) data for each segment and sub-segment
- Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
- Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
- Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions and acquisitions in the past five years of companies profiled
- Extensive company profiles comprising of company overview, company insights, product benchmarking and SWOT analysis for the major market players
- The current as well as the future market outlook of the industry with respect to recent developments (which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
Table Of Contents
Table of Contents
Global Cancer Drugs Market by Manufacturers, Regions, Type and Application, Forecast to 2026
1 Report Overview
1.1 Definition and Specification
1.2 Report Overview
1.2.1 Manufacturers Overview
1.2.2 Regions Overview
1.2.3 Type Overview
1.2.4 Application Overview
1.3 Industrial Chain
1.3.1 Cancer Drugs Overall Industrial Chain
1.3.2 Upstream
1.3.3 Downstream
1.4 Industry Situation
1.4.1 Industrial Policy
1.4.2 Product Preference
1.4.3 Economic/Political Environment
1.5 SWOT Analysis
2 Market Assessment by Type
2.1 Chemotherapy Sales (K Units), Revenue (M USD) and Growth Rate 2014-2020
2.2 Targeted Therapy Sales (K Units), Revenue (M USD) and Growth Rate 2014-2020
2.3 Immunotherapy Sales (K Units), Revenue (M USD) and Growth Rate 2014-2020
2.4 Hormonal Therapy (Biologic Therapy) Sales (K Units), Revenue (M USD) and Growth Rate 2014-2020
2.5 Others Sales (K Units), Revenue (M USD) and Growth Rate 2014-2020
3 Asia Pacific Cancer Drugs Market Assessment by Type
3.1 Asia Pacific Market Performance (Sales, Revenue)
3.2 Key Players in Asia Pacific
4 North America Cancer Drugs Market Assessment by Type
4.1 North America Market Performance (Sales, Revenue)
4.2 Key Players in North America
5 Europe Cancer Drugs Market Assessment by Type
4.1 Europe Market Performance (Sales, Revenue)
4.2 Key Players in Europe
6 South America Cancer Drugs Market Assessment by Type
4.1 South America Market Performance (Sales, Revenue)
4.2 Key Players in South America
7 Middle Easr and Africa Cancer Drugs Market Assessment by Type
4.1 Middle Easr and Africa Market Performance (Sales, Revenue)
4.2 Key Players in Middle Easr and Africa
8 World Cancer Drugs Market Assessment by Type
8.1 Asia Pacific Cancer Drugs Market Assessment by Application (Consumption and Market Share)
8.2 North America Cancer Drugs Market Assessment by Application (Consumption and Market Share)
8.3 Europe Cancer Drugs Market Assessment by Application (Consumption and Market Share)
8.4 South America Cancer Drugs Market Assessment by Application (Consumption and Market Share)
8.5 Middle East and Africa Cancer Drugs Market Assessment by Application (Consumption and Market Share)
9 Company Profiles/Analysis
9.1 Roche
9.1.1 Roche Profiles
9.1.2 Roche Product Portfolio
9.1.3 Roche Cancer Drugs Business Performance
9.1.4 Roche Cancer Drugs Business Development and Market Status
9.2 Novartis
9.2.1 Novartis Profiles
9.2.2 Novartis Product Portfolio
9.2.3 Novartis Cancer Drugs Business Performance
9.2.4 Novartis Cancer Drugs Business Development and Market Status
9.3 Celgene
9.3.1 Celgene Profiles
9.3.2 Celgene Product Portfolio
9.3.3 Celgene Cancer Drugs Business Performance
9.3.4 Celgene Cancer Drugs Business Development and Market Status
9.4 Bristol-Myers Squibb
9.4.1 Bristol-Myers Squibb Profiles
9.4.2 Bristol-Myers Squibb Product Portfolio
9.4.3 Bristol-Myers Squibb Cancer Drugs Business Performance
9.4.4 Bristol-Myers Squibb Cancer Drugs Business Development and Market Status
9.5 Amgen
9.5.1 Amgen Profiles
9.5.2 Amgen Product Portfolio
9.5.3 Amgen Cancer Drugs Business Performance
9.5.4 Amgen Cancer Drugs Business Development and Market Status
9.6 Johnson & Johnson
9.6.1 Johnson & Johnson Profiles
9.6.2 Johnson & Johnson Product Portfolio
9.6.3 Johnson & Johnson Cancer Drugs Business Performance
9.6.4 Johnson & Johnson Cancer Drugs Business Development and Market Status
9.7 Pfizer
9.7.1 Pfizer Profiles
9.7.2 Pfizer Product Portfolio
9.7.3 Pfizer Cancer Drugs Business Performance
9.7.4 Pfizer Cancer Drugs Business Development and Market Status
9.8 Takeda
9.8.1 Takeda Profiles
9.8.2 Takeda Product Portfolio
9.8.3 Takeda Cancer Drugs Business Performance
9.8.4 Takeda Cancer Drugs Business Development and Market Status
9.9 Eli Lilly
9.9.1 Eli Lilly Profiles
9.9.2 Eli Lilly Product Portfolio
9.9.3 Eli Lilly Cancer Drugs Business Performance
9.9.4 Eli Lilly Cancer Drugs Business Development and Market Status
9.10 AstraZeneca
9.10.1 AstraZeneca Profiles
9.10.2 AstraZeneca Product Portfolio
9.10.3 AstraZeneca Cancer Drugs Business Performance
9.10.4 AstraZeneca Cancer Drugs Business Development and Market Status
9.11 Astellas
9.12 Merck & Co.
9.13 Sanofi
9.14 Bayer
9.15 Biogen Idec
9.16 Eisai
9.17 Teva
9.18 Otsuka
9.19 Merck KGaA
9.20 Ipsen
9.21 AbbVie
9.22 Gilead Sciences
10 World Cancer Drugs Market Assessment by Players
10.1 Global Cancer Drugs Sales (K Units) and Market Share by Players 2014-2020
10.2 Global Cancer Drugs Revenue (M USD) and Market Share by Players 2014-2020
10.3 Global Cancer Drugs Price (USD/Unit) of Players 2014-2020
10.4 Global Cancer Drugs Gross Margin of Players 2014-2020
10.5 Market Concentration
11 Regional Market Performance by Segment of Players
11.1 North America
11.1.1 North America Cancer Drugs Sales Assessment of Players 2014-2020
11.1.2 North America Cancer Drugs Revenue Assessment of Players 2014-2020
11.1.3 North America Cancer Drugs Price Assessment of Players 2014-2020
11.1.4 North America Cancer Drugs Gross Margin Assessment of Players 2014-2020
11.1.5 Market Concentration
11.2 Europe
11.2.1 Europe Cancer Drugs Sales Assessment of Players 2014-2020
11.2.2 Europe Cancer Drugs Revenue Assessment of Players of Manufacturers 2014-2020
11.2.3 Europe Cancer Drugs Price Assessment of Players 2014-2020
11.2.4 Europe Cancer Drugs Gross Margin Assessment of Players 2014-2020
11.2.5 Market Concentration
11.3 Asia-Pacific Market Performance for Manufacturers
11.3.1 Asia-Pacific Cancer Drugs Sales Assessment of Players 2014-2020
11.3.2 Asia-Pacific Cancer Drugs Revenue Assessment of Players 2014-2020
11.3.3 Asia-Pacific Cancer Drugs Price Assessment of Players 2014-2020
11.3.4 Asia-Pacific Cancer Drugs Gross Margin Assessment of Players 2014-2020
11.3.5 Market Concentration
11.4 South America Market Performance for Players
11.4.1 South America Cancer Drugs Sales Assessment of Players 2014-2020
11.4.2 South America Cancer Drugs Revenue Assessment of Players 2014-2020
11.4.3 South America Cancer Drugs Price Assessment of Players 2014-2020
11.4.4 South America Cancer Drugs Gross Margin Assessment of Players 2014-2020
11.4.5 Market Concentration
11.5 Middle East and Africa Market Performance for Players
11.5.1 Middle East and Africa Cancer Drugs Sales Assessment of Players 2014-2020
11.5.2 Middle East and Africa Cancer Drugs Revenue Assessment of Players 2014-2020
11.5.3 Middle East and Africa Cancer Drugs Price Assessment of Players 2014-2020
11.5.4 Middle East and Africa Cancer Drugs Gross Margin Assessment of Players 2014-2020
11.5.5 Market Concentration
12 Regional Market Performance by Segment of Countries
12.1 Asia Pacific
12.1.1 Asia Pacific Cancer Drugs Sales by Countries/Regions 2014-2020
12.1.2 Asia Pacific Cancer Drugs Revenue by Countries/Regions 2014-2020
12.1.3 Asia Pacific Cancer Drugs Average Price by Countries/Regions 2014-2020
12.2 North America
12.2.1 North America Cancer Drugs Sales by Countries/Regions 2014-2020
12.2.2 North America Cancer Drugs Revenue by Countries/Regions 2014-2020
12.2.3 North America Cancer Drugs Average Price by Countries/Regions 2014-2020
12.3 Europe
12.3.1 Europe Cancer Drugs Sales by Countries/Regions 2014-2020
12.3.2 Europe Cancer Drugs Revenue by Countries/Regions 2014-2020
12.3.3 Europe Cancer Drugs Average Price by Countries/Regions 2014-2020
12.4 South America
12.4.1 South America Cancer Drugs Sales by Countries/Regions 2014-2020
12.4.2 South America Cancer Drugs Revenue by Countries/Regions 2014-2020
12.4.3 South America Cancer Drugs Average Price by Countries/Regions 2014-2020
12.5 Middle East and Africa
12.5.1 Middle East and Africa Cancer Drugs Sales by Countries/Regions 2014-2020
12.5.2 Middle East and Africa Cancer Drugs Revenue by Countries/Regions 2014-2020
12.5.3 Middle East and Africa Cancer Drugs Average Price by Countries/Regions 2014-2020
13 Technology and Opportunity
13.1 Technology
13.2 Market Opportunity
14 World Cancer Drugs Sales & Revenue Forecast 2021-2026
14.1 World Cancer Drugs Sales and Revenue Forecast by Regions 2021-2026
14.1.1 World Cancer DrugsSales and Market Share by Regions
14.1.2 World Cancer DrugsRevenue and Market Share by Regions
15 Asia Cancer Drugs Market Forecast 2021-2026
15.1 Sales and Revenue (M USD) Forecast by Type, 2021-2026
15.1.1 Chemotherapy
15.1.2 Targeted Therapy
15.1.3 Immunotherapy
15.1.4 Hormonal Therapy (Biologic Therapy)
15.1.5 Others
15.2 Consumption Forecast by Application, 2021-2026
16 North America Cancer Drugs Market Forecast 2021-2026
16.1 Sales and Revenue (M USD) Forecast by Type, 2021-2026
16.1.1 Chemotherapy
16.1.2 Targeted Therapy
16.1.3 Immunotherapy
16.1.4 Hormonal Therapy (Biologic Therapy)
16.1.5 Others
16.2 Consumption Forecast by Application, 2021-2026
17 Europe Cancer Drugs Market Forecast 2021-2026
17.1 Sales and Revenue (M USD) Forecast by Type, 2021-2026
17.1.1 Chemotherapy
17.1.2 Targeted Therapy
17.1.3 Immunotherapy
17.1.4 Hormonal Therapy (Biologic Therapy)
17.1.5 Others
17.2 Consumption Forecast by Application, 2021-2026
18 South America Cancer Drugs Market Forecast 2021-2026
18.1 Sales and Revenue (M USD) Forecast by Type, 2021-2026
18.1.1 Chemotherapy
18.1.2 Targeted Therapy
18.1.3 Immunotherapy
18.1.4 Hormonal Therapy (Biologic Therapy)
18.1.5 Others
18.2 Consumption Forecast by Application, 2021-2026
19 Middle East and Africa Cancer Drugs Market Forecast 2021-2026
19.1 Sales and Revenue (M USD) Forecast by Type, 2021-2026
19.1.1 Chemotherapy
19.1.2 Targeted Therapy
19.1.3 Immunotherapy
19.1.4 Hormonal Therapy (Biologic Therapy)
19.1.5 Others
19.2 Consumption Forecast by Application, 2021-2026
20 Price (USD/Unit) and Gross Profit Forecast
20.1 Global Cancer Drugs Price (USD/Unit) Trend 2021-2026
20.2 Global Cancer Drugs Gross Profit Trend 2021-2026
21 Conclusion
